Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658446 | 0.92 | EDNRB (0.61) | EDNRBEDNRA | |
| SCHEMBL6316175 | 0.87 | EDNRB (0.81) | EDNRBEDNRA | |
| SCHEMBL6313613 | 0.86 | EDNRB (0.49) | EDNRBEDNRA | |
| SCHEMBL6314876 | 0.84 | EDNRB (0.51) | EDNRBEDNRA | |
| SCHEMBL6314856 | 0.79 | EDNRB (0.52) | EDNRBEDNRA | |
| SCHEMBL6313623 | 0.78 | EDNRB (0.51) | EDNRBEDNRA | |
| SCHEMBL6663213 | 0.77 | EDNRB (0.44) | EDNRBEDNRA | |
| SCHEMBL6319417 | 0.77 | EDNRB (0.50) | EDNRBEDNRA | |
| SCHEMBL6321599 | 0.77 | EDNRB (1.00) | EDNRB | |
| SCHEMBL6657735 | 0.77 | EDNRB (0.77) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.